Earnings ·
Reports Q3 net sales of $9.7M, raises full-year revenue outlook to $39M-$42M
ECORelectroCore, Inc.
electroCore reported third-quarter net sales of $9.7 million, a 12% increase year-over-year, driven by growth in U.S. prescription sales through the Department of Veterans Affairs and Quell product lines. The company posted a GAAP net loss of $1.3 million, an improvement of 61% from the prior year period, while Adjusted EBITDA loss narrowed to $0.7 million. Management revised its full-year 2026 revenue guidance upward to a range of $39 million to $42 million and introduced preliminary 2027 guidance anticipating 30% to 40% revenue growth over the updated 2026 base. The company also highlighted operational efficiencies, including improved return on advertising spend and a transition to a new distribution agreement for federal sales. electroCore is a bioelectronic technology company developing non-invasive devices for headache treatment and general wellness.